|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
159,210,000 |
Market
Cap: |
1.34(B) |
Last
Volume: |
2,204,422 |
Avg
Vol: |
2,183,785 |
52
Week Range: |
$3.36 - $8.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 346 |
Guru Rank Value : 6 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Reasons Bryan M. |
Chief Financial Officer |
|
2017-05-14 |
4 |
D |
$17.65 |
$12,443 |
D/D |
(705) |
104,348 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2017-05-14 |
4 |
D |
$17.65 |
$8,860 |
D/D |
(502) |
88,967 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2017-05-14 |
4 |
D |
$17.65 |
$57,098 |
D/D |
(3,235) |
101,944 |
|
- |
|
Nestor Michael |
President, Impax Specialty |
|
2017-05-14 |
4 |
D |
$17.65 |
$52,985 |
D/D |
(3,002) |
112,166 |
|
- |
|
Nestor Michael |
President, Impax Specialty |
|
2017-05-12 |
4 |
S |
$17.11 |
$11,977 |
D/D |
(700) |
115,168 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
17,317 |
89,469 |
|
- |
|
Nestor Michael |
President, Impax Specialty |
|
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,272 |
115,868 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,272 |
105,053 |
|
- |
|
Boothe Douglas |
President, Generics Division |
|
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,272 |
85,872 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
23,272 |
105,179 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2017-02-26 |
4 |
D |
$14.05 |
$84,497 |
D/D |
(6,014) |
81,907 |
|
- |
|
Nestor Michael |
President, Impax Specialty |
|
2017-02-26 |
4 |
D |
$14.05 |
$78,596 |
D/D |
(5,594) |
92,596 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2017-02-26 |
4 |
D |
$14.05 |
$80,296 |
D/D |
(5,715) |
81,781 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2017-02-26 |
4 |
D |
$14.05 |
$60,429 |
D/D |
(4,301) |
72,152 |
|
- |
|
Buchi J Kevin |
Director |
|
2016-11-23 |
4 |
A |
$0.00 |
$0 |
D/D |
8,020 |
8,020 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2016-10-26 |
4 |
D |
$21.35 |
$36,167 |
D/D |
(1,694) |
76,453 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2016-10-26 |
4 |
D |
$21.35 |
$25,812 |
D/D |
(1,209) |
87,496 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2016-10-25 |
4 |
D |
$21.80 |
$39,872 |
D/D |
(1,829) |
78,147 |
|
- |
|
Boothe Douglas |
President, Generics Division |
|
2016-08-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,600 |
62,600 |
|
- |
|
Benet Leslie Z |
Director |
|
2016-08-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,025 |
18,108 |
|
- |
|
Bierly Rick |
Director |
|
2016-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,895 |
4,895 |
|
- |
|
Benet Leslie Z |
Director |
|
2016-08-15 |
4 |
S |
$22.81 |
$230,199 |
D/D |
(10,092) |
30,133 |
|
- |
|
Benet Leslie Z |
Director |
|
2016-08-15 |
4 |
OE |
$6.55 |
$131,000 |
D/D |
20,000 |
40,225 |
|
- |
|
Nestor Michael |
President, Impax Specialty |
|
2016-08-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,906) |
98,190 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2016-05-23 |
4 |
D |
$32.12 |
$35,171 |
D/D |
(1,095) |
87,921 |
|
- |
|
180 Records found
|
|
Page 3 of 8 |
|
|